

---

# RISING FOOD PRICES SHOWCASE THE NEED FOR GREATER INNOVATIONS IN AGRICULTURE

Christopher Gannatti – Global Head of Research  
06/16/2022

At WisdomTree, we believe that one of the biggest megatrends over the coming decades will relate to biotechnology. Part of that relates to human health, and we have already seen how innovations in [messenger RNA \(mRNA\)](#) have provided incredibly novel vaccine applications with respect to COVID-19.

However, with an expanding global population and greater attention being paid to sustainability, novel approaches to agriculture may be at least as important in the long run.

## Making It Concrete: Tomatoes

Scientists at the John Innes Centre in Norwich have created tomatoes that are a source of vitamin D. They made small deletions in the plant's genome that prompted the plants to accumulate provitamin D3, which can be converted to vitamin D in sunlight. A single upgraded tomato could provide around 20% of the recommended daily allowance of the vitamin.<sup>1</sup>

But how can the UK encourage the appearance of something like the tomatoes described here on supermarket shelves? The answer is by recognizing the complex journey of genetically modified organisms in Europe and gradually adjusting the legislative environment.

## Different Countries, Different Views

In recent years, there has been no shortage of polarizing issues. Questions around the safety and desirability of genetically modified crops has generated strong responses, particularly in Europe. In certain respects, the legal environment has made it very challenging to picture a reality where any of these potential innovations could widely proliferate in Europe.

However, it would not be appropriate to paint every country across the continent with the same brush. Even if there is a common regulatory structure and common market, that doesn't always mean all countries and people share the same views.

It is in these different views that change can sometimes emerge.

## The U.K. Presents: The Genetic Technology (Precision Breeding) Bill<sup>2</sup>

It's true that following [Brexit](#), the U.K. has struck out on its own away from the European Union, thereby creating flexibility. Environment Secretary George Eustice said:

*Outside the EU, we are free to follow the science. These precision technologies allow us to speed up the breeding of plants that have natural resistance to diseases and better use of soil nutrients so we can have higher yields with fewer pesticides and fertilizers. The U.K. has some incredible academic centers of excellence and they are poised to lead the way.*

Precision breeding technologies could have a range of benefits, such as:

1. They will give U.K. scientists the power to help farmers and producers develop plant

varieties and animals with beneficial traits that could also occur through traditional breeding and natural processes.

2. It can create safer food by removing allergens and preventing the formation of harmful compounds in food.

### Sustainability at the Forefront

It's possible that precision breeding techniques can produce crops with fewer inputs, such as pesticides and fertilizers. Globally, between 20% and 40% of all crops grown are lost to pests and disease, but it's possible that precision breeding can increase both pest and disease resistance. NFU Vice President David Exwood said:

*This science-based legislative change has the potential to offer a number of benefits to U.K. food production and to the environment and will provide farmers and growers with another tool in the toolbox as we look to overcome the challenges of feeding an ever-growing population while tackling the climate crisis.*

### Will the European Union Follow?

According to an announcement from the European Commission, published on April 29, 2021, a study on new genomic techniques (NGTs) showed that NGTs have the potential to contribute to a more sustainable food system as part of the objectives of the European Green Deal and the Farm to Fork Strategy.

The study also found that the current genetically modified organism (GMO) legislation, adopted in 2001, is not fit for purpose for these innovative technologies. The Commission announced a wide and open consultation process to discuss the design of a new legal framework for these biotechnologies. Commissioner for Health and Food Safety, Stella Kyriakides, said:

*The study we published today concludes that New Genomic Techniques can promote the sustainability of agricultural production, in line with the objectives of our Farm to Fork Strategy. With the safety of consumers and the environment as the guiding principle, now is the moment to have an open dialogue with citizens, Member States and the European Parliament to jointly decide the way forward for the use of these biotechnologies in the EU.*

We cannot, of course, guarantee any outcomes, but what's clear is that the legal framework and views are evolving, possibly with the focus on sustainability as a catalyst. There is no question that now in 2022, as we type these words, the agricultural system is facing stress due to the Russia/Ukraine crisis. It's important to give all possible solutions and mitigating factors due consideration.

### Conclusion: Look for Agricultural Applications of the BioRevolution to Grow

WisdomTree has been following the BioRevolution for some time, and it's clear that the focus on human health came first. Over time, we expect the focus on agriculture and food to grow, and if the legal frameworks in certain regions of the world tend toward being more permissive rather than less, it will only help things along in that regard. Those interested in a specific strategy that may touch on these trends, consider the [WisdomTree BioRevolution Fund \(WDNA\)](#).

### Important Risks Related to this Article

*Christopher Gannatti is an employee of WisdomTree UK Limited, a European subsidiary of WisdomTree Asset Management Inc.'s parent company, WisdomTree Investments, Inc.*

There are risks associated with investing, including possible loss of principal. The Fund invests in BioRevolution companies, which are companies significantly transformed by advancements in genetics and biotechnology. BioRevolution companies face intense competition and potentially rapid product obsolescence. These companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations or policies. Additionally, BioRevolution companies may be subject to risks associated with genetic analysis. The Fund invests in the securities included in, or representative of, its Index regardless

of their investment merit and the Fund does not attempt to outperform its Index or take defensive positions in declining markets. The composition of the Index is governed by an Index Committee and the Index may not perform as intended. Please read the Fund's prospectus for specific details regarding the Fund's risk profile.

For the top 10 holdings of WDNA please visit the Fund's fund detail page at <https://www.wisdomtree.com/investments/etfs/megatrends/wdna>

For standardized performance and the most recent month-end performance click [here](#) NOTE, this material is intended for electronic use only. Individuals who intend to print and physically deliver to an investor must print the monthly performance report to accompany this blog.

#### Related Funds

+ [WisdomTree BioRevolution Fund](#)

View the online version of this article [here](#).

**IMPORTANT INFORMATION**

**U.S. investors only:** Click [here](#) to obtain a WisdomTree ETF prospectus which contains investment objectives, risks, charges, expenses, and other information; read and consider carefully before investing.

There are risks involved with investing, including possible loss of principal. Foreign investing involves currency, political and economic risk. Funds focusing on a single country, sector and/or funds that emphasize investments in smaller companies may experience greater price volatility. Investments in emerging markets, currency, fixed income and alternative investments include additional risks. Please see prospectus for discussion of risks.

Past performance is not indicative of future results. This material contains the opinions of the author, which are subject to change, and should not to be considered or interpreted as a recommendation to participate in any particular trading strategy, or deemed to be an offer or sale of any investment product and it should not be relied on as such. There is no guarantee that any strategies discussed will work under all market conditions. This material represents an assessment of the market environment at a specific time and is not intended to be a forecast of future events or a guarantee of future results. This material should not be relied upon as research or investment advice regarding any security in particular. The user of this information assumes the entire risk of any use made of the information provided herein. Neither WisdomTree nor its affiliates, nor Foreside Fund Services, LLC, or its affiliates provide tax or legal advice. Investors seeking tax or legal advice should consult their tax or legal advisor. Unless expressly stated otherwise the opinions, interpretations or findings expressed herein do not necessarily represent the views of WisdomTree or any of its affiliates.

The MSCI information may only be used for your internal use, may not be reproduced or re-disseminated in any form and may not be used as a basis for or component of any financial instruments or products or indexes. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each entity involved in compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties. With respect to this information, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including loss profits) or any other damages ([www.msci.com](http://www.msci.com))

Jonathan Steinberg, Jeremy Schwartz, Rick Harper, Christopher Gannatti, Bradley Krom, Tripp Zimmerman, Michael Barrer, Anita Rausch, Kevin Flanagan, Brendan Loftus, Joseph Tenaglia, Jeff Weniger, Matt Wagner, Alejandro Saltiel, Ryan Krystopowicz, Jianing Wu, and Brian Manby are registered representatives of Foreside Fund Services, LLC.

WisdomTree Funds are distributed by Foreside Fund Services, LLC, in the U.S. only. You cannot invest directly in an index.

DEFINITIONS

**Messenger RNA (mRNA)**: A single-stranded RNA molecule that is complementary to one of the DNA strands of a gene. The mRNA is an RNA version of the gene that leaves the cell nucleus and moves to the cytoplasm where proteins are made. During protein synthesis, an organelle called a ribosome moves along the mRNA, reads its base sequence, and uses the genetic code to translate each three-base triplet, or codon, into its corresponding amino acid.

**Brexit**: an abbreviation of “British exit” that mirrors the term Grexit. It refers to the possibility that Britain will withdraw from the European Union.